Get started
Author

Mo Dan

Observed institution: CSPC Pharmaceutical Group
ORCID: 0000-0003-0601-5345
Observed ORCID: 0000-0003-0601-5345
OpenAlex ID: A5151818693
Selection of Payloads for Antibody–Drug Conjugates Targeting Ubiquitously Expressed Tumor-Associated Antigens: a Case Study
2022 · Bing Yao, Xiao Gao, et al. · The AAPS Journal · 13
Abstract 4338: SYS6042, a novel anti-TROP2 pH-sensitive antibody-drug conjugate (ADC) with improved therapeutic window
2025 · Yancui Wang, Xiao Gao, et al. · Cancer Research · 1
Table S12 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Data from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Figure S4 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Figure S10 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Table S8 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Table S13 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Table S9 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Figure 2 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Table 1 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Figure S3 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Table S2 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Table S10 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Figure 4 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Supplementary Methods from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Figure S8 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Figure S7 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Figure 5 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Figure S5 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Table S1 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Figure S6 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Figure S1 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Figure 3 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Table S6 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Works count: 34
Citation count: 14
H-index: 1
I10-index: 1
Year
Topic
Type